Business
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline
About this update from Shattuck Labs, Inc.
[{"type":"text","content":"– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients at the European Society of Hematology (EHA) 2024 Annual Meeting – – Enrollment ongoing in the randomized, controlled Phase 1B dose-expansion cohort in frontline HR-MDS patients – – Announced Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the treatment of AML– AUSTIN, TX and DURHAM, NC, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended June 30, 2024 and provided recent business highlights. “Our data presentation at EHA last quarter included complete remission rates for both HR-MDS and TP53m AML patients treated with SL-172154 in combination with AZA that exceeded the expected complete remission rates for AZA alone. It is encouraging to see in our EHA presentation that our complete remission rate improved as the number of patients in each cohort increased, since our initial data presented at ASH in December of 2023. The next milestone for this program is to see how these response rates translate to an overall survival benefit, and those data will mature over the second half of this year,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “In parallel, we are pleased that enrollment has begun so swiftly in our randomized, controlled expansion cohort in frontline HR-MDS patients. We look forward to sharing clinical updates from these trials in the months ahead.” Second Quarter 2024 Business Highlights and Other Recent Developments SL-172154 (SIRPα-Fc-CD40L) Phase 1B Trial of SL-172154 in Frontline HR-MDS and TP53m AML HR-MDS Announced updated interim data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. These data were featured in a poster presentation during the EHA 2024 Congress. Observed 67% Objective Response Rate (ORR) in frontline ...